Calabrese C, et al. - The therapeutic impact of inhaled nasal budesonide (100 μg per nostril twice daily) was clinically assessed in COPD patients with chronic rhinitis comorbidity after being treated for 2 months. They found total scores of COPD assessment test (CAT), Sinonasal Outcome Test (SNOT 22), and modified Medical Research Council dyspnea scale saw statistically significant improvements following two months of treatment with nasal budesonide. They also found a significant link between CAT and SNOT 22 total scores at baseline and after treatment. Based on the findings, it is important to carefully assess chronic nasal symptoms in all COPD patients. Treatment with nasal budesonide was suggested to be clinically beneficial in terms of COPD symptoms and quality of life.